REOPRO Drug Profile

Summary for Tradename: REOPRO

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for REOPRO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for REOPRO

Recent Clinical Trials for REOPRO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
St. Louis University	Phase 2
Janssen Services, LLC	Phase 2
SOS Attaque Cérébrale	Phase 4

See all REOPRO clinical trials

Recent Litigation for REOPRO

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Acerta Pharma B.V. v. Cipla Limited	2024-05-16
Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd.	2023-02-28
FENNEC PHARMACEUTICALS, INC. v. CIPLA LIMITED	2023-01-10

See all REOPRO litigation

PTAB Litigation

Petitioner	Date
Sandoz Inc.	2023-02-03
Instrumentation Laboratory Company et al.	2019-04-24
Instrumentation Laboratory Company	2019-02-21

See all REOPRO litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for REOPRO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for REOPRO Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for REOPRO Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575		2031-02-15	Patent claims search
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575		2025-05-24	Patent claims search
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575		2028-01-09	Patent claims search
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575		2025-05-24	Patent claims search
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575		2028-11-25	Patent claims search
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575		2032-02-15	Patent claims search
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575		2033-08-02	Patent claims search

REOPRO Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Biologic Drug: ReoPro (Abciximab)

Introduction

ReoPro, also known as abciximab, is a biologic drug used primarily as an antiplatelet agent to prevent platelet aggregation. It is commonly administered during coronary interventions such as angioplasty and stent placement. Here, we delve into the market dynamics and financial trajectory of ReoPro.

Market Size and Growth

The global ReoPro (abciximab) market is projected to experience significant growth over the next few years. As of 2024, the market is valued at approximately $1.08 billion and is expected to grow to $1.62 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period[1].

Regional Market Analysis

The market for ReoPro is segmented across various regions, including North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

• North America: This region, including the U.S. and Canada, is a significant market for ReoPro due to the high prevalence of cardiovascular diseases and advanced healthcare infrastructure.
• Europe: Countries such as Germany, France, the UK, and Italy contribute substantially to the European market.
• Asia Pacific: This region, including China, Japan, South Korea, and India, is expected to show rapid growth due to increasing healthcare spending and a rising population with cardiovascular conditions[1].

Market Segmentation by Type and Application

The ReoPro market is segmented based on the type of formulation and application.

• Type: The drug is available in 20ml and 50ml formulations.
• Application: It is primarily used in hospitals and clinics, with other applications including research and emergency medical services[1].

Key Producers and Competitive Landscape

Several pharmaceutical companies are key players in the ReoPro market.

• Janssen Biotech: Known for its extensive portfolio of biologic drugs, Janssen Biotech is a major player in the ReoPro market.
• Orifarm Group: This company is involved in the distribution and marketing of various pharmaceutical products, including ReoPro.
• Eli Lilly: Although not the primary manufacturer, Eli Lilly has been involved in the distribution and marketing of ReoPro in certain regions[1].

Financial Performance and Revenue Forecast

The financial performance of ReoPro is closely tied to its sales and revenue.

• Revenue by Region: The revenue generated from ReoPro varies significantly by region. North America and Europe are the largest contributors due to their well-established healthcare systems and high demand for cardiovascular treatments[1].
• Sales Estimates and Forecasts: The sales of ReoPro are expected to increase steadily, driven by the growing need for antiplatelet agents in coronary interventions. The forecast indicates a consistent growth in sales from 2019 to 2030, with a notable increase in revenue during the period from 2025 to 2030[1].

Impact of COVID-19

The COVID-19 pandemic has had a mixed impact on the ReoPro market. While it highlighted the importance of agile supply chain management and vaccine development, it also led to temporary disruptions in healthcare services, affecting the demand for non-COVID related treatments. However, the long-term demand for ReoPro remains robust due to the ongoing need for cardiovascular interventions[1].

Industry Trends and Growth Factors

Several trends and factors are driving the growth of the ReoPro market.

• Increasing Prevalence of Cardiovascular Diseases: The rising incidence of heart diseases and the need for effective antiplatelet agents are key drivers.
• Advancements in Healthcare Infrastructure: Improvements in healthcare facilities, especially in emerging markets, are increasing access to advanced treatments like ReoPro.
• Competitive Landscape: The entry of new players and the expansion of existing ones are contributing to market growth[1][4].

Challenges and Financial Restrictions

Despite the growth potential, the ReoPro market faces several challenges.

• Financial Restrictions: Funding and financial restrictions can limit the accessibility of ReoPro, especially in regions with limited healthcare budgets[3].
• Competition from Biosimilars: The emergence of biosimilar drugs could pose a challenge to the market share of ReoPro, although the impact is expected to be minimal in the short term[4].

Key Takeaways

• The global ReoPro market is projected to grow significantly, driven by increasing demand for antiplatelet agents.
• Regional markets, particularly North America and Europe, are key contributors to the revenue.
• The competitive landscape is dynamic, with major pharmaceutical companies playing significant roles.
• Despite challenges, the long-term outlook for ReoPro remains positive due to the growing need for cardiovascular treatments.

FAQs

What is ReoPro (abciximab) used for?

ReoPro (abciximab) is used as an antiplatelet agent to prevent platelet aggregation during coronary interventions such as angioplasty and stent placement.

Who are the key producers of ReoPro?

Key producers include Janssen Biotech, Orifarm Group, and other pharmaceutical companies involved in its distribution and marketing.

How is the ReoPro market segmented?

The market is segmented by type (20ml and 50ml formulations) and application (hospitals, clinics, and other medical settings).

What is the projected growth rate of the ReoPro market?

The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.0% from 2024 to 2030.

How has the COVID-19 pandemic affected the ReoPro market?

The pandemic has had a mixed impact, with temporary disruptions in healthcare services but a long-term increase in demand due to the ongoing need for cardiovascular treatments.

Sources

1. QY Research: Global ReoPro(Abciximab) Market Insights, Forecast to 2030.
2. Medicure Inc.: Investor Presentation, November 25, 2022.
3. PubMed: Variability in abciximab (ReoPro) prescribing: evidence based or not?
4. BCC Research: Biologic Therapeutic Drugs: Technologies and Global Markets.